Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.
<h4>Background</h4>Implication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant efavirenz based antiviral therapy and anti-tubercular drug induced liver injury (DILI) has not been yet studied. We performed a prospective case-control association study to identif...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Public Library of Science (PLoS)
2011
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/e1ce99c0bd4644399fbce95ac165a999 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|